Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Following our exploration of RNA therapeutics and their delivery challenges, this episode focuses on how Nuvec® has been engineered to overcome these barriers, offering a next-generation solution for RNA drug delivery.

CEO Nigel Theobald explains how Nuvec’s unique spiky silica nanoparticle structure protects RNA, enhances cell uptake, and enables efficient payload release. Key advantages include:

Protection & Stability – Shields RNA from degradation, enabling both injectable and oral delivery.

Efficient Cell Uptake & Release – Positively charged for easier entry into cells and designed to escape the endosome, allowing the RNA to function effectively.

Scalability & Cost Efficiency – Simple, low-cost manufacturing process compared to lipid nanoparticles and viral vectors.

Multi-RNA Loading – The ability to carry multiple siRNA or mRNA payloads, enabling complex gene therapies and oncology treatments targeting multiple pathways.

This episode provides a deep dive into the science behind Nuvec® and its potential to transform RNA therapeutics.

Next, we’ll explore Inflammatory Bowel Disease: Prevalence and N4 Pharma’s Approach, the first therapeutic area where Nuvec® will be applied.

Watch now and submit your questions below.

Nuvec: Revolutionising Drug Delivery